Physician profile
Michael J Singh
NPI 1972596542
$293.02
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.93 · 2020: $128 · 2021: $67.92 · 2022: $51.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $115.18 | 2019-2021 | |
| Allergan, INC. | $65.37 | 2019-2020 | |
| Pfizer INC. | $60.41 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $18.51 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.35 | 2022 | |
| Lilly USA, LLC | $16.20 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.